Drug intelligence / Profile preview

RT-4000

Development stage: Preclinical
Lead developer: RenaissThera
Modality: Small Molecules
Administration: Oral

Overview

RT-4000 is an oral small-molecule dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR), currently under development by RenaissThera. Designed to address the limitations of injectable peptide-based therapies, RT-4000 aims to provide a cost-effective and scalable treatment for type 2 diabetes mellitus and obesity. The molecule was identified and optimized using an AI-powered platform to achieve potent dual agonism, which synergistically enhances insulin secretion and promotes weight loss. As of mid-2025, the program was in the lead optimization stage, with plans to advance toward IND-enabling studies.

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on RT-4000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT-4000.

Explore the full profile